By Colin Kellaher

Elanco Animal Health Inc. on Tuesday said it has formally submitted its planned $7.6 billion acquisition of Bayer AG's animal-health business to the European Commission for regulatory approval.

The Greenfield, Ind., animal-health company said the filing of Form CO notification triggers the start of the statutory review period, adding that the commission now has until June 8 to make its decision.

Elanco previously announced planned divestitures of businesses with revenue of $120 million to $140 million in a bid to gain regulatory blessing for the deal.

The company has also fully secured financing to complete the transaction, which it said remains on track with its original mid-2020 closing plans.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

April 14, 2020 11:32 ET (15:32 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Grafico Azioni Bayer (TG:BAYN)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Bayer
Grafico Azioni Bayer (TG:BAYN)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Bayer